Literature DB >> 33874801

Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among pregnant women.

Rachel K Scott1,2,3, Shawnika J Hull4, Robin C Richards2, Kristen Klemmer3, Frida Salmoran1, Jim C Huang1,5.   

Abstract

HIV prevention is critically important during pregnancy, however, pre-exposure prophylaxis (PrEP) is underutilized. We conducted a survey of pregnant and non-pregnant women in a high HIV prevalence community in Washington D.C. to evaluate determinants of PrEP initiation during pregnancy. 201 pregnant women and a reference population of 1103 non-pregnant women completed the survey. Among pregnant women, mean age was 26.9 years; the majority were Black with household-incomes below the federal poverty level. Despite low perceived risk of HIV acquisition and low prior awareness of PrEP, 10.5% of respondents planned to initiate PrEP during pregnancy. Pregnant women identified safety, efficacy, and social network and medical provider support as key factors in PrEP uptake intention. The belief that PrEP will "protect (their) baby from HIV" was associated with PrEP uptake intention during pregnancy. Concerns regarding maternal/fetal side effects, and safety in pregnancy or while breastfeeding were not identified as deterrents to uptake intention. When compared to a nonpregnant sample, there were no significant differences in uptake intention between the two samples. These findings support the need for prenatal educational interventions to promote HIV prevention during pregnancy, as well as interventions that center on the role of providers in the provision of PrEP.

Entities:  

Keywords:  Behavioral intention; HIV prevention; Human Immunodeficiency Virus (HIV); Integrated Model of Behavior Prediction; high prevalence; pre-exposure prophylaxis (PrEP); pregnancy; psychosocial determinants; reasoned action approach; women

Mesh:

Substances:

Year:  2021        PMID: 33874801      PMCID: PMC8523573          DOI: 10.1080/09540121.2021.1916870

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  40 in total

1.  Nigerian male sexual activity during pregnancy.

Authors:  H E Onah; G C Iloabachie; S N Obi; F O Ezugwu; J N Eze
Journal:  Int J Gynaecol Obstet       Date:  2002-02       Impact factor: 3.561

2.  Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006.

Authors:  Guthrie S Birkhead; Wendy P Pulver; Barbara L Warren; Sheila Hackel; Deborah Rodríguez; Lou Smith
Journal:  Obstet Gynecol       Date:  2010-06       Impact factor: 7.661

3.  Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.

Authors:  Nicolas Salvadori; Bo Fan; Waralee Teeyasoontranon; Nicole Ngo-Giang-Huong; Siriluk Phanomcheong; Anita Luvira; Achara Puangsombat; Arunrat Suwannarat; Ussanee Srirompotong; Chaiwat Putiyanun; Tim R Cressey; Luc Decker; Woottichai Khamduang; Linda Harrison; Camlin Tierney; John A Shepherd; Athena P Kourtis; Marc Bulterys; George K Siberry; Gonzague Jourdain
Journal:  Clin Infect Dis       Date:  2019-06-18       Impact factor: 9.079

4.  Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.

Authors:  Athena P Kourtis; Jeffrey Wiener; Liming Wang; Bo Fan; John A Shepherd; Lili Chen; Wei Liu; Colin Shepard; Linhong Wang; Ailin Wang; Marc Bulterys
Journal:  Pediatr Infect Dis J       Date:  2018-11       Impact factor: 2.129

5.  Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners.

Authors:  Kerry A Thomson; James Hughes; Jared M Baeten; Grace John-Stewart; Connie Celum; Craig R Cohen; Kenneth Ngure; James Kiarie; Nelly Mugo; Renee Heffron
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

6.  PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists.

Authors:  Andrew E Petroll; Jennifer L Walsh; Jill L Owczarzak; Timothy L McAuliffe; Laura M Bogart; Jeffrey A Kelly
Journal:  AIDS Behav       Date:  2017-05

Review 7.  Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.

Authors:  Lynne M Mofenson; Rachel C Baggaley; Ioannis Mameletzis
Journal:  AIDS       Date:  2017-01-14       Impact factor: 4.177

8.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.

Authors:  Renee Heffron; Nelly Mugo; Ting Hong; Connie Celum; Mark A Marzinke; Kenneth Ngure; Stephen Asiimwe; Elly Katabira; Elizabeth A Bukusi; Josephine Odoyo; Edna Tindimwebwa; Nulu Bulya; Jared M Baeten
Journal:  AIDS       Date:  2018-07       Impact factor: 4.177

10.  Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?

Authors:  Dvora L Joseph Davey; Jillian Pintye; Jared M Baeten; Grace Aldrovandi; Rachel Baggaley; Linda-Gail Bekker; Connie Celum; Benjamin H Chi; Thomas J Coates; Jessica E Haberer; Renee Heffron; John Kinuthia; Lynn T Matthews; James McIntyre; Dhayendre Moodley; Lynne M Mofenson; Nelly Mugo; Landon Myer; Andrew Mujugira; Steven Shoptaw; Lynda Stranix-Chibanda; Grace John-Stewart
Journal:  J Int AIDS Soc       Date:  2020-01       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.